poisar

Stocks · News reference

EU Medicines Agency Backs Expanded Use of Roche's Gazyvaro for Systemic Lupus Erythematosus

Fiscal.ai

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the expanded use of Roche's Gazyvaro (obinutuzumab) for treating systemic lupus erythematosus.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchZacks.Com

    Is ProShares S&P Technology Dividend Aristocrats ETF (TDV) a Strong ETF Right Now?

    ProShares S&P Technology Dividend Aristocrats ETF (TDV) is a smart beta ETF with $270.5 million in assets that tracks technology companies with dividend aristocrat status. The fund has delivered strong performance with 17.89% year-to-date returns and 20.67% one-year returns, though it carries higher volatility (beta of 1.13) and concentration risk with only 38 holdings. The 0.45% expense ratio is competitive, and the fund offers dividend yield of 1.06%, making it suitable for investors seeking technology exposure with dividend focus.